Press Releases Items Per Page 102550 News Category FinancialGeneral Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Nektar Reports on Advancements with Pain and Oncology Clinical Pipeline at Investor and Analyst R&D Day Oct 08, 2015 Nektar Submits Investigational New Drug Application (IND) for NKTR-214 To Treat Solid Tumor Malignancies Oct 07, 2015 Nektar Closes Direct Private Placement with TPG Special Situations Partners of $250 Million of Senior Secured Notes Due in 2020 Oct 06, 2015 Nektar to Host Research & Development Day for Analysts and Investors on October 8th Oct 01, 2015 Nektar Presents Data Demonstrating that NKTR-214, a CD122-Biased Immunostimulatory Cytokine, Induces Durable and Specific Anti-Tumor Immunity As a Single-Agent and When Combined with Checkpoint Inhibitors in Preclinical Models Sep 21, 2015 Nektar Announces Receipt of $40 Million Milestone Payment Resulting from First Commercial Sale of MOVENTIG® (naloxegol) Tablets in Major European Market Sep 01, 2015 Nektar Therapeutics Reports Financial Results for the Second Quarter of 2015 Aug 05, 2015 Nektar to Announce Financial Results for the Second Quarter 2015 on Wednesday, August 5, 2015, After Close of U.S.-Based Financial Markets Jul 29, 2015 UPDATE: Baxalta's BAX 855 Pivotal Data Published in Blood Shows Potential to Provide Strong Bleed Prevention with Twice Weekly Dosing for Patients with Hemophilia A Jul 16, 2015 Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine Jun 02, 2015 Pagination First page « first Previous page ‹ previous … Page 22 Page 23 Page 24 Page 25 Current page 26 Page 27 Page 28 Page 29 Page 30 … Next page next › Last page last »